NCT01248858View on ClinicalTrials.gov

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.

PHASE1TerminatedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

December 3, 2010

Primary Completion Date

January 30, 2014

Study Completion Date

April 23, 2015

Conditions
Cancer
Interventions
DRUG

GSK2126458 and GSK1120212

GSK2126458 and GSK1120212 are experimental treatments for patients with cancer.

Trial Locations (4)

20132

GSK Investigational Site, Milan

37203

GSK Investigational Site, Nashville

27599-7305

GSK Investigational Site, Chapel Hill

M5G 2M9

GSK Investigational Site, Toronto

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01248858 - Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors. | Biotech Hunter | Biotech Hunter